Your browser doesn't support javascript.
loading
Teprotumumab: a new avenue for the management of moderate-to-severe and active Graves' orbitopathy?
Piantanida, E; Bartalena, L.
Affiliation
  • Piantanida E; Department of Medicine and Surgery, Endocrine Unit, University of Insubria, ASST dei Sette Laghi, Ospedale di Circolo, Viale Borri, 57, Varese, Italy.
  • Bartalena L; Department of Medicine and Surgery, Endocrine Unit, University of Insubria, ASST dei Sette Laghi, Ospedale di Circolo, Viale Borri, 57, Varese, Italy. luigi.bartalena@uninsubria.it.
J Endocrinol Invest ; 40(8): 885-887, 2017 08.
Article in En | MEDLINE | ID: mdl-28634704
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Graves Disease / Graves Ophthalmopathy Limits: Humans Language: En Journal: J Endocrinol Invest Year: 2017 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Graves Disease / Graves Ophthalmopathy Limits: Humans Language: En Journal: J Endocrinol Invest Year: 2017 Document type: Article